The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG

Expert Review of Vaccines

Volumn 15, Issue 8, 2016, Pages 1041-1053

  Skurnik, David ^a   Cywes Bentley, Colette ^a   Pier, Gerald B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibiotic resistance; Capsule; Conjugate vaccine; Monoclonal antibody; Ply N acetyl glucosamine

Indexed keywords

ANTIBODY; COMPLEMENT; N ACETYLGLUCOSAMINE; POLY N ACETYL GLUCOSAMINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG; BACTERIAL VACCINE; FUNGUS VACCINE; MALARIA VACCINE; POLY-N-ACETYL GLUCOSAMINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ARTICLE; BACILLUS SUBTILIS; BACTERICIDAL ACTIVITY; COMPLEMENT DEPOSITION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; GENE EXPRESSION; GENE LOCUS; HUMAN; INFECTION PREVENTION; INNATE IMMUNITY; MULTIDRUG RESISTANCE; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; YERSINIA PESTIS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; VACCINATION;

ACETYLGLUCOSAMINE; ANIMALS; BACTERIAL VACCINES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FUNGAL VACCINES; HUMANS; IMMUNIZATION, PASSIVE; MALARIA VACCINES; VACCINATION;

EID: 84961215242     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1159135     Document Type: Article

References (74)

1. Achievements in Public Health. 1900-1999: control of infectious diseases. MMWR Morb Mort Wkly Rep. 1999;48(29):621–629.
2. P.H.Makela Conjugate vaccines–a breakthrough in vaccine development. SE Asian J Trop Med Public Health. 2003;34(2):249–253.
3. K.Houser, K.Subbarao. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015;17(3):295–300.
4. M.Rubens, V.Ramamoorthy, A.Saxena, et al. HIV vaccine: Recent advances, current roadblocks, and future directions. J Immunol Res. 2015;2015:560347.
5. S.Sinha, B.Medhi, R.Sehgal. Challenges of drug-resistant malaria. Parasite. 2014;21:61.
6. C.Cywes-Bentley, D.Skurnik, T.Zaidi, et al. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci USA. 2013;110(24):E2209–2218.•• This paper describes the broad-based expression of PNAG among a range of microbes and documents the protective efficacy of polyclonal and MAb to PNAG against these pathogens. It also highlights the common in vivo expression of PNAG in infected tissues.
7. M.L.Gening, T.Maira-Litran, A.Kropec, et al. Synthetic β-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun. 2012;78(2):764–772.• This paper documents the utility of synthetic oligosaccharides as a basis for a conjugate vaccine to PNAG. It also validates the need for non-acetylated glucosamines as the PNAG glycoform needed top-induced protective immunity.
8. C.Kelly-Quintos, A.Kropec, S.Briggs, et al. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis. 2012-2019;192(11):2005.
9. T.Maira-Litran, A.Kropec, D.A.Goldmann, et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun. 2005;73(10):6752–6762.
10. C.Pozzi, K.Wilk, J.C.Lee, et al. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. Plos One. 2012;7(10):e46648.
11. D.Vlock, J.C.Lee, A.Kropec-Huebner, et al. Pre-clinical and initial phase i evaluations of a fully human monoclonal antibody directed against the PNAG surface polysaccharide on Staphylococcus aureus. Abstracts of the 50th ICAAC 2010; ASM Press; Abstract G1-1654/329;,2010.
12. M.Tojo, N.Yamashita, D.A.Goldmann, et al. Isolation and characterization of a capsular polysaccharide adhesin from Staphylococcus epidermidis. J Infect Dis. 1988;157(4):713–722.
13. D.Mack, W.Fischer, A.Krokotsch, et al. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis. J Bacteriol. 1996;178(1):175–183.
14. D.McKenney, J.Hubner, E.Muller, et al. The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccharide/adhesin. Infect Immun. 1998;66(10):4711–4720.
15. D.McKenney, K.L.Pouliot, Y.Wang, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science. 1999;284(5419):1523–1527.
16. S.E.Cramton, C.Gerke, N.F.Schnell, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun. 1999;67(10):5427–5433.
17. L.Baldassarri, G.Donnelli, A.Gelosia, et al. Purification and characterization of the staphylococcal slime-associated antigen and its occurrence among Staphylococcus epidermis clinical isolates. Infect Immun. 1996;64(8):3410–3415.
18. E.Muller, J.Hübner, N.Gutierrez, et al. Isolation and characterization of transposon mutants of Staphylococcus epidermidis deficient in capsular polysaccharide/adhesin and slime. Infect Immun. 1993;61(2):551–558.
19. T.Maira-Litran, A.Kropec, C.Abeygunawardana, et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun. 2002;70(8):4433–4440.
20. J.G.Joyce, C.Abeygunawardana, Q.Xu, et al. Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureus. Carbohydr Res. 2003;338(9):903–922.
21. J.P.O’Gara. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol Lett. 2007;270(2):179–188.
22. X.Wang, J.F.Preston3rd, T.Romeo. The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required for biofilm formation. J Bacteriol. 2004;186(9):2724–2734.•• In 2004, Romeo and colleagues found the genes encoding the PNAG biosynthetic proteins in E. coli, leading to the identification of these genes in a large number of Gram-negative pathogens.
23. A.H.K.Choi, L.Slamti, F.Y.Avci, et al. The pgaABCD locus of Acinetobacter baumanniiencodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol. 2009;191(19):5953–5963.
24. D.Skurnik, M.R.DavisJr., D.Benedetti, et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis. 1709-1718;205(11):2012.
25. K.-M.Chen, M.-K.Chiang, M.Wang, et al. The role of pgaC in Klebsiella pneumoniae virulence and biofilm formation. Microb Pathog. 2014;77:89–99.
26. G.Parise, M.Mishra, Y.Itoh, et al. Role of a putative polysaccharide locus in Bordetella biofilm development. J Bacteriol. 2006;189(3):750–760.
27. D.Roux, C.Cywes-Bentley, Y.F.Zhang, et al. Identification of poly-N-acetylglucosamine as a major polysaccharide component of the Bacillus subtilis biofilm matrix. J Biol Chem. 2015;290(31):19261–19272.
28. A.Kropec, T.Maira-Litran, K.K.Jefferson, et al. Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect Immun. 2005;73(10):6868–6876.
29. S.Subashchandrabose, S.N.Smith, R.R.Spurbeck, et al. Genome-wide detection of fitness genes in uropathogenic Escherichia coli during systemic infection. PLoS Pathog. 2013;9(12):e1003788.
30. N.Cerca, K.K.Jefferson, R.Oliveira, et al. Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state. Infect Immun. 2006;74(8):4849–4855.
31. C.Heilmann, O.Schweitzer, C.Gerke, et al. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol Microbiol. 1996;20(5):1083–1091.• This publication provided the initial identification of the genetic locus encoding proteins involved in PNAG synthesis and insight into the function of these proteins.
32. C.Gerke, A.Kraft, R.Süssmuth, et al. Characterization of the N-acetylglucosaminyltransferase activity involved in the biosynthesis of the Staphylococcus epidermidis polysaccharide intercellular adhesin. J Biol Chem. 1998;273(29):18586–18593.
33. A.G.Bobrov, O.Kirillina, S.Forman, et al. Insights into Yersinia pestis biofilm development: topology and co-interaction of Hms inner membrane proteins involved in exopolysaccharide production. Environ Microbiol. 2008;10(6):1419–1432.
34. D.Skurnik, D.Roux, S.Pons, et al. Extended spectrum antibodies protective against carbapenemase producing Enterobacteriaceae. J Antimicrob Chemother. 2016 Jan 7. pii: dkv448. [Epub ahead of print]
35. G.B.Whitfield, L.S.Marmont, P.L.Howell. Enzymatic modifications of exopolysaccharides enhance bacterial persistence. Front Microbiol. 2015;6:471.• This review article presents an outstanding overview of the biosynthesis of PNAG.
36. L.V.Bentancor, J.M.O’Malley, C.Bozkurt-Guzel, et al. Poly-N-acetyl-beta-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun. 2012;80(2):651–656.
37. P.Yoong, C.Cywes-Bentley, G.B.Pier. Poly-N-acetylglucosamine expression by wild-type Yersinia pestis is maximal at mammalian, not flea, temperatures. MBio. 2012;3(4):e00217–00212.
38. C.Kelly-Quintos, L.A.Cavacini, M.R.Posner, et al. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect Immun. 2006;74(5):2742–2750.•• This paper describes the production and characterization of MAb F598 to PNAG, no in clinical trials in humans and also used as the reagent to detect PNAG among microbial pathogens.
39. N.Cerca, T.Maira-Litrán, K.K.Jefferson, et al. Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide. Proc Natl Acad Sci USA. 2007;104(18):7528–7533.
40. J.B.Kaplan, K.Velliyagounder, C.Ragunath, et al. Genes involved in the synthesis and degradation of matrix polysaccharide in Actinobacillus actinomycetemcomitans and Actinobacillus pleuropneumoniae biofilms. J Bacteriol. 2004;186(24):8213–8220.
41. N.Ramasubbu, L.M.Thomas, C.Ragunath, et al. Structural analysis of Dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen Actinobacillus actinomycetemcomitans. J Mol Biol. 2005;349(3):475–486.•• The use of Dispersin B as a tool in identifying and studying PNAG is exceptional. This paper reports on its properties and its specificity for the β-1-6-linkage between the glucosamines in PNAG.
42. D.Skurnik, A.Kropec, D.Roux, et al. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis. 2012;55(9):1188–1197.
43. D.Skurnik, M.Merighi, M.Grout, et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest. 2010;120(9):3220–3233.
44. A.A.Grachev, A.G.Gerbst, M.L.Gening, et al. NMR and conformational studies of linear and cyclic oligo-(1–>6)-beta-D-glucosamines. Carbohydr Res. 2011;346(15):2499–2510.
45. I.Verdier, G.Durand, M.Bes, et al. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J Clin Microbiol. 2007;45(3):725–729.
46. H.Shinefield, S.Black, A.Fattom, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346(7):491–496.
47. R.S.Daum, B.Spellberg. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis. 2012;54(4):560–567.
48. Y.Kojima, M.Tojo, D.A.Goldmann, et al. Antibody to the capsular polysaccharide/adhesin protects rabbits against catheter-related bacteremia due to coagulase-negative staphylococci. J Infect Dis. 1990;162(2):435–441.
49. S.Takeda, G.B.Pier, Y.Kojima, et al. Protection against endocarditis due to Staphylococcus epidermidis by immunization with capsular polysaccharide/adhesin. Circulation. 1991;84(6):2539–2546.
50. P.M.Farrell, J.Collins, L.S.Broderick, et al. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology. 2009;252(2):534–543.
51. Z.Li, M.R.Kosorok, P.M.Farrell, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. Jama. 2005;293(5):581–588.
52. X.Lu, D.Skurnik, C.Pozzi, et al. A poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli. Mbio. 2014;5(2):e00974-00914-e00974-00914.
53. R.Wallis, D.A.Mitchell, R.Schmid, et al. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiol. 2010;215(1):1–11.
54. N.Brouwer, K.M.Dolman, M.Van Houdt, et al. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol. 4124-4132;180(6):2008.
55. W.S.Garrett, G.M.Lord, S.Punit, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007;131(1):33–45.
56. M.M.Perez, A.Prenafeta, J.Valle, et al. Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl beta-1,6 glucosamine specific antibody production using biofilm-embedded bacteria. Vaccine. 2009;27(17):2379–2386.
57. N.Cerca, K.K.Jefferson, T.Maira-Litran, et al. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun. 2007;75(7):3406–3413.
58. M.Lukacova, I.Barak, J.Kazar. Role of structural variations of polysaccharide antigens in the pathogenicity of Gram-negative bacteria. Clin Microbiol Infect. 2008;14(3):200–206.
59. G.Samuel, P.Reeves. Biosynthesis of O-antigens: genes and pathways involved in nucleotide sugar precursor synthesis and O-antigen assembly. Carbohydr Res. 2503-2519;338(23):2003.
60. C.Whitfield. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem. 2006;75:39–68.
61. P.Nordmann, G.Cuzon, T.Naas. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet. 2009;9(4):228–236.
62. L.Poirel, J.D.Pitout, P.Nordmann. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2007;2(5):501–512.
63. J.K.Rasheed, B.Kitchel, W.Zhu, et al. New Delhi metallo-beta-lactamase-producing Enterobacteriaceae, United States. Emerg Infect Dis. 2013;19(6):870–878.
64. T.C.Darton, C.J.Blohmke, V.S.Moorthy, et al. Design, recruitment, and microbiological considerations in human challenge studies. Lancet. 2015;15(7):840–851.
65. M.M.Hobbs, P.F.Sparling, M.S.Cohen, et al. Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC. Front Microbiol. 2011;2:123.
66. M.B.Laurens, P.Billingsley, A.Richman, et al. Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: A new model for controlled human malaria infection. Plos One. 2013;8(7):e68969.
67. M.Labandeira-Rey, D.Dodd, K.R.Fortney, et al. A Haemophilus ducreyi CpxR deletion mutant is virulent in human volunteers. J Infect Dis. 2011;203(12):1859–1865.
68. A.J.Pollard, J.Savulescu, J.Oxford, et al. Human microbial challenge: the ultimate animal model. Lancet. 2012;12(12):903–905.
69. C.S.Waddington, T.C.Darton, C.Jones, et al. An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis. 2014;58(9):1230–1240.
70. D.J.Little, N.C.Bamford, V.Pokrovskaya, et al. Structural basis for the de-N-acetylation of poly-beta-1,6-N-acetyl-D-glucosamine in Gram-positive bacteria. J Biol Chem. 2014;289(52):35907–35917.
71. D.J.Little, G.Li, C.Ing, et al. Modification and periplasmic translocation of the biofilm exopolysaccharide poly-beta-1,6-N-acetyl-D-glucosamine. Proc Natl Acad Sci USA. 2014;111(30):11013–11018.
72. M.Nissen, H.Marshall, P.Richmond, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine. 2015;33(15):1846–1854.
73. S.M.Lattar, M.Noto Llana, P.Denoel, et al. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun. 2014;82(1):83–91.
74. A.Taylor, S.S.Foo, R.Bruzzone, et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev. 2015;268(1):340–364.